C4 Therapeutics (CCCC) Insider Roy Buys 62,000 Shares
Donna Roy Grogan acquired 62,000 shares of C4 Therapeutics on June 24, 2026, signaling confidence in the company's direction.
Reviewed by automated data checks against the source filing. How we make and check alerts
Grogan Donna Roy bought 62,000 shares of C4 Therapeutics, Inc. ($CCCC) on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CCCC is up 2.1% after 1 week, down 20.0% after 1 month and down 34.8% to date (from the $4.25 close on Jun 24, 2026).
CCCC
C4 Therapeutics, Inc.
Key Points
- On June 24, 2026, Donna Roy Grogan bought 62,000 shares of C4 Therapeutics, Inc. at a price of $4.40 per share, totaling approximately $272,800.
- The stock has seen a range between $1.69 and $5.17 over the past year, highlighting its volatility in the biotechnology sector.
- JP Morgan recently initiated coverage of C4 Therapeutics with an Overweight rating and set a price target of $10.00 on October 9, 2026.
Get $CCCC trade alerts by text
We text you when insiders, Congress or big funds trade $CCCC. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated C4 Therapeutics, Inc. alert may contain errors. Disclosures
C4 Therapeutics Insider Grogan Buys Shares
On June 24, 2026, Donna Roy Grogan, an insider at C4 Therapeutics, Inc. (NasdaqGS: CCCC), bought 62,000 shares of the company. The shares were purchased at a price of $4.40 each, bringing the total value of the transaction to approximately $272,800.
Multiple Insiders Buy on the Same Day
Grogan wasn't the only insider making moves on June 24. Ronald Cooper, Utpal Koppikar, Owen Hughes, Stephen Fawell, Laura Bessen, and Steven Hoerter each acquired 62,000 shares of C4 Therapeutics on the same day. This collective buying action reflects a strong belief in the company's potential, especially as it continues to develop its clinical-stage products.
Stock Performance and Market Context
C4 Therapeutics has seen its stock price fluctuate between $1.69 and $5.17 over the past year, indicating some volatility in the market. Just before Grogan's purchase, the stock closed at $3.39, showing a potential upside for investors as it trades near its 52-week high. The company operates in the biotechnology sector, focusing on therapies that target disease-causing proteins, which is critical in today's healthcare landscape.
Analysts Set New Price Targets
On October 9, 2026, JP Morgan initiated coverage of C4 Therapeutics with an Overweight rating and set a price target of $10.00. This positive outlook could further attract investor interest, especially given that the average price target among analysts is around $13.33, suggesting room for growth.
What C4 Therapeutics, Inc. Does
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. It focuses on developing innovative treatments for diseases like cancer by targeting specific proteins that contribute to disease progression. The company is advancing several promising candidates, including Cemsidomide for multiple myeloma and CFT8919 for non-small cell lung cancer.
What’s Next for C4 Therapeutics?
The company is set to report its next earnings on November 5, 2026. Investors will be keen to see how its financials align with the ongoing development of its product pipeline. As always, it's important to note that insider transactions reflect past decisions and may not indicate current holdings. Keep an eye on upcoming filings for further insights into the company's direction.
Related Filing Alerts
Source: Grogan Donna Roy's Form 4 filing on $CCCC (Jun 24, 2026). Find the original filing: CCCC Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts